Gilead Prices $5 Billion of Senior Unsecured Notes

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ:GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $5 billion, in an underwritten, registered public offering, consisting of five tranches:

• $500 million of 1.950% senior notes maturing in 2022
• $750 million of 2.500% senior notes maturing in 2023
• $1,250 million of 2.950% senior notes maturing in 2027
• $750 million of 4.000% senior notes maturing in 2036
• $1,750 million of 4.150% senior notes maturing in 2047

The senior notes are rated A by Standard & Poor’s and A3 by Moody’s. The
offering is expected to close September 20, 2016, subject to customary
closing conditions.
Gilead intends to use the net proceeds from the offering for general
corporate purposes, which may include the repayment of debt, working
capital, payment of dividends, the repurchase of its outstanding common
stock pursuant to its authorized share repurchase program and future
acquisitions.
Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P. Morgan
Securities LLC are acting as lead joint book-running managers in the
offering. The offering of the securities is being made only by means of
a prospectus supplement and the accompanying base prospectus, which is
filed as part of Gilead’s effective shelf registration statement on Form
S-3 (File No. 333-194298), copies of which may be obtained from:

An electronic copy of the prospectus supplement and the accompanying
base prospectus may also be obtained at no charge at the Securities and
Exchange Commission’s website at https://www.sec.gov/.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the securities, nor shall there
be any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases. Gilead has operations in more than 30
countries worldwide, with headquarters in Foster City, California.
Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors, including the current
market demand for these types of securities and the securities of
Gilead, Gilead’s ability to consummate the offering in the currently
anticipated timeframe or at all and the negotiations between Gilead and
the underwriters. These risks, uncertainties and other factors could
cause actual results to differ materially from those referred to in the
forward-looking statements. The reader is cautioned not to rely on these
forward-looking statements. These and other risks that could impact the
offering are described in detail in Gilead’s Quarterly Report on Form
10-Q for the quarter ended June 30, 2016, as filed with the U.S.
Securities and Exchange Commission, and may be updated by the risk
factors set forth in any subsequent filing by Gilead with the U.S.
Securities and Exchange Commission. All forward-looking statements are
based on information currently available to Gilead, and Gilead assumes
no obligation to update any such forward-looking statements.

For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.